Independent · evidence-anchored·Reviewed by the GLPHelper Medical Team
EN·ES
glp·helper
Find a Provider →
glphelper.com/tirzepatide/florida/delray-beach
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022 (Mounjaro) · November 2023 (Zepbound)Rx · Subcutaneous injection · Once weekly

Tirzepatide® providers &
prescriptions in Delray Beach, FL

Verified Tirzepatide providers in Delray Beach, FL. Checked against the NPI registry, never ranked by who pays us.[7]

city providers
32
as of today
§ 02Provider directory: Florida
32 of 32 shown

Find a Tirzepatide provider in Florida.

Every entry is checked against the federal NPI registry. We do not accept payment for placement.

Filter →
Type
Provider
City
Insurance / phone
Browse by Florida city · /tirzepatide/florida/{city}
Boca Raton
26.37°N
42 →
Coral Springs
26.27°N
31 →
Wellington
26.65°N
28 →
West Palm Beach
26.75°N
41 →
Fort Lauderdale
41 →
Plantation
26.13°N
36 →
§ 03Getting Tirzepatide in Delray Beach
32 providers · Delray Beach, FL

How to get Tirzepatide in Delray Beach.

32 GLP-1 prescribers and 7 local resource types are on record for Delray Beach, plus 3 nearby towns in the directory.

Prescribers in Delray Beach
32 prescribers
32 GLP-1 prescribers in Delray Beach, most listed as Family Medicine (12), Internal Medicine (11) and Internal Medicine, Endocrinology, Diabetes & Metabolism (4). Any Florida-licensed physician, nurse practitioner, or PA can prescribe Tirzepatide, over video or in person. The nearest towns on record are Boca Raton (42 providers), Coral Springs (31 providers) and Wellington (28 providers).
Around the prescription in Delray Beach
7 listed nearby
26 dietitians, 7 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 4 places to move are on record near Delray Beach.
Medicaid (weight loss)
Diabetes only
As of April 2026, Florida Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Florida’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Mounjaro and Zepbound. It acts on two gut-hormone pathways, GIP and GLP-1.

Tirzepatide is a once-weekly injection sold by Eli Lilly as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). It is the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one, which is associated with greater average weight loss than single GLP-1 agonists.[2][3]

In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% on placebo. In the SURPASS-2 head-to-head diabetes trial, tirzepatide produced larger HbA1c and weight reductions than semaglutide 1 mg.[1]

At a glanceMultiple (brand-specific)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022 (Mounjaro) · November 2023 (Zepbound)
Approved use
Type 2 diabetes (Mounjaro) · chronic weight management (Zepbound)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Delray Beach

Delray Beach, Florida has a population of 66,846 people. The adult obesity rate in Delray Beach is an age-adjusted estimate of 27.7%, 1.9 percentage points below the Florida state rate of 29.6%. Diagnosed diabetes reaches 10.4% of adults in Delray Beach. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 23.1% of adults in Delray Beach.

of Delray Beach adults have obesity
27.7%
diagnosed diabetes
10.4%
no regular physical activity
23.1%

Age-adjusted estimates for Delray Beach, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight losshow tirzepatide titration works
§ 05Support around Tirzepatide in Delray Beach
6 dietitians

The prescription is one part. Here is the rest, in Delray Beach.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Delray Beach, FL, ordered as the registry lists them, never by who pays us.

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Kimberly Altman, Dietitian
RD
Registered dietitian
27385 Saint Lucie Ln
Call 609-509-4969NPI 1225235708
Brooke Andrews, MS, RDN, CISSN
RD
Registered dietitian
4337 Sylvester Palm Dr
Call 727-688-9584NPI 1578969978
Samantha Barone, RD
RD
Registered dietitian
4600 Linton Blvd Ste 250
Call 561-500-4673NPI 1053834796
Sondra Braude, RD, LD/N
RD
Registered dietitian
120 Se 4Th Ave
Call 561-266-8866NPI 1568840072
Shaleen Burgess
RD
Registered dietitian
4800 Linton Blvd Ste F107
Call 561-455-1336NPI 1306250493
Leslie Burman, R.D., L.D
RD
Registered dietitian
22971 Via Desonrisa Del Norte
Call 561-789-7000NPI 1003069204

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Lisa Benbasat, RD, LD/N
NUTRITIONIST
Nutritionist
225 S Congress Ave
Call 561-274-1350NPI 1366972804
Ligia Chiodi, CDR
NUTRITIONIST
Nutritionist
4800 Linton Blvd
Call 561-495-1973NPI 1699764548
Natalie Elledge, LMT
NUTRITIONIST
Nutritionist · Education
2275 S Federal Hwy Ste 280
Call 561-418-9325NPI 1013689223
Liliane Laurent, MPH,LDN
NUTRITIONIST
Nutritionist
225 S Congress Ave
Call 561-274-3100NPI 1336247287
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURMOUNT weight-management program and the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) across 72 weeks. Mean weight change was −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% with placebo. A majority of patients on the higher doses lost ≥20% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (15 mg)
−20.9%
SURMOUNT-1, 72 wk vs −3.1% placebo[2]
Mean weight change (5 mg)
−15.0%
SURMOUNT-1, 72 wk[2]
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average tirzepatide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12 to 19%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Zepbound (no insurance)
$1,000 to $1,300
per month
Brand-name retail; Lilly self-pay vials lower for some doses[6]
Cash, Mounjaro (no insurance)
$1,000 to $1,200
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Zepbound is on-label but frequently requires PA
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Tirzepatide providers in Florida

NPI-verified Tirzepatide (tirzepatide) prescribers and clinics, never ranked by who pays us.

Weight loss doctors in Florida
Prescribers verified against the federal NPI registry.
Weight loss clinics in Florida
Clinics running GLP-1 programs, telehealth & in-person.
Tirzepatide in other states

Find NPI-verified Tirzepatide (tirzepatide) doctors, clinics, and pharmacies in the states we cover, never ranked by who pays us.

Tirzepatide in Alabama→Tirzepatide in Alaska→Tirzepatide in Arizona→Tirzepatide in Arkansas→Tirzepatide in California→Tirzepatide in Colorado→Tirzepatide in Connecticut→Tirzepatide in Delaware→Tirzepatide in Florida→Tirzepatide in Georgia→Tirzepatide in Hawaii→Tirzepatide in Idaho→Tirzepatide in Illinois→Tirzepatide in Indiana→Tirzepatide in Iowa→Tirzepatide in Kansas→Tirzepatide in Kentucky→Tirzepatide in Louisiana→Tirzepatide in Maine→Tirzepatide in Maryland→Tirzepatide in Massachusetts→Tirzepatide in Michigan→Tirzepatide in Minnesota→Tirzepatide in Mississippi→Tirzepatide in Missouri→Tirzepatide in Montana→Tirzepatide in Nebraska→Tirzepatide in Nevada→Tirzepatide in New Hampshire→Tirzepatide in New Jersey→Tirzepatide in New Mexico→Tirzepatide in New York→Tirzepatide in North Carolina→Tirzepatide in North Dakota→Tirzepatide in Ohio→Tirzepatide in Oklahoma→Tirzepatide in Oregon→Tirzepatide in Pennsylvania→Tirzepatide in Rhode Island→Tirzepatide in South Carolina→Tirzepatide in South Dakota→Tirzepatide in Tennessee→Tirzepatide in Texas→Tirzepatide in Utah→Tirzepatide in Vermont→Tirzepatide in Virginia→Tirzepatide in Washington→Tirzepatide in West Virginia→Tirzepatide in Wisconsin→Tirzepatide in Wyoming→
Related GLP-1 research
the tirzepatide dosing schedule
Starting dose, step-ups, and the 2.5-to-15 mg ladder.
do oral GLP-1 pills work
Pills and drops vs injections: what the evidence supports.
Zepbound side effects
Label rates by dose next to placebo, and the head-to-head trial with Wegovy.
§ 09Frequently asked: Tirzepatide in Florida

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Tirzepatide is the active molecule in both Eli Lilly products. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. They are the same drug with different approved indications, and insurers treat them as separate products.[1]